肝动脉灌注化疗在肝癌转化治疗中的研究进展

原发性肝癌是目前我国第4位常见恶性肿瘤及第2位肿瘤致死病因,严重威胁我国人民的生命和健康。原发性肝癌中>90%病人是肝细胞癌(以下简称肝癌),其中66%的病人初诊时已处于中晚期,失去手术机会。因此,中晚期肝癌的防治及转化治疗尤为重要。肝动脉灌注化疗(HAIC)是中晚期肝癌的重要治疗手段,以其为核心的转化治疗展现出较好的肿瘤反应率及手术转化率。笔者深入分析国内外HAIC相关研究进展,系统阐述其发展历史及以HAIC为核心的转化治疗。

Research progress of hepatic arterial infusion chemotherapy in the conversion therapy of hepatocellular carcinoma

Primary liver cancer is the fourth most common malignancy and the second most common cause of cancer death in China,posing a serious threat to the health of Chinese people.Hepatocellular carcinoma(HCC)represents more than 90%of primary liver cancers,among them 66%of patients are with intermediate-advanced HCC.Therefore,prevention strategies and conversion therapies to patients with intermediate-advanced HCC are particularly important.Hepatic arterial infusion chemotherapy(HAIC)is one of the important treatment methods to treat intermediate-advanced HCC.The tumor objective response rates and surgery conversion rates of HAIC-based conversion therapies are promising.The authors review the history of HAIC and the HAIC-based conversion therapies in this article.